Around the world more than 10 million people suffer from Parkinson’s disease, a chronic movement disorder that causes the brain chemicals that control the body’s movement and coordination to fail. Though more than 60,000 people are diagnosed with Parkinson’s disease (PD) annually in the U.S. alone, diagnosing with certainty is still a challenge – and usually occurs later than would be ideal for effective treatment.
A team of Israeli researchers and doctors are hoping to change that. Israel21c reports.
The Israeli startup BioShai has a game-changing product on the horizon: PDx, the world’s first simple blood test for the early diagnosis of PD.
The test results can be combined with clinical data, providing a more accurate diagnosis to help physicians decide on the best course of treatment at a much earlier stage.
Why is early detection important?
“Having a diagnosis at an earlier stage can lead to a more precise treatment and a higher quality of life for the patient,” says BioShai CEO Jennifer Yarden, who has a PhD in medical science and formerly was responsible for clinical and commercial development of diagnostic assays and kits at Glycominds. Yarden is also CEO and cofounder of Curewize Health.
“Offering a simple and inexpensive test for the diagnosis of Parkinson’s is considered essential for the development of neuroprotective therapy,” she explains, “because by the time a patient has the many movement symptoms associated with Parkinson’s, a majority of the dopamine-producing neurons are lost or become impaired by the disease.”